NEKTAR THERAPEUTICS Q3 2026 FINANCIAL RESULTS - NEKTAR THERAPEUTICS

Explicit Guidance:

• Financial Guidance (FY2026):
  • Non-cash royalty revenue: ~$38 million for the full year.
  • R&D expenses: $185–$200 million range (includes ~$5–$10 million non-cash depreciation/SBC).
  • G&A expenses: ~$65 million for the full year (within prior range).
  • Non-cash interest expense: ~$28 million for the full year.
  • Cash and Investments: Expected to end 2026 with >$840 million (above top end of Q2 guidance range of $815–$840M).
• Clinical Data Readouts:
  • Atopic Dermatitis (AD) top-line data: Summer 2028 from Zenith AD studies.
  • BLA Filing Goal: By end of 2029.
  • Alopecia Areata (AA) data readout: 2029 (Zenith AA study).
  • Resolve AD off-treatment data: Q1 2027.
  • Type 1 Diabetes (T1D) first cohort data: Late 2027 or beginning 2028.
  • Vitiligo proof-of-concept data: Late 2027 or early 2028.
• Share Count: Not explicitly guided; no specific buyback or dividend programs mentioned.

Business-Segment Outlook:

• Atopic Dermatitis (AD):
  • Label Strategy: Aiming for the broadest possible label supporting first-line use (biologic/JAK naive), second/third-line use (experienced), adolescents (12+), monotherapy, and combination therapy with topical corticosteroids (TCS).
  • Study Structure: Three pivotal studies (Zenith AD1, AD2, AD3) enrolling ~1,500 patients total.
    • Zenith AD1: Monotherapy in JAK/biologic-naive patients.
    • Zenith AD2: Combination with TCS in both naive and experienced patients (protocol modified based on FDA/EMA/PMDA feedback to ensure global registration).
    • Zenith AD3: Combination/Monotherapy in biologic/JAK-experienced patients.
  • Dosing Potential: Early data suggests potential for quarterly dosing after 52 weeks, and potentially every six months for deep responders.
• Alopecia Areata (AA):
  • Market Outlook: Forecast to reach ~$5.2 billion by 2033 (Decision Research Group).
  • Clinical Program: Single global registrational study (Zenith AA) enrolling ~850 patients (ages 12+).
  • Differentiation: Focus on durability of response post-treatment to mitigate hair regrowth loss associated with JAK inhibitors.
  • Long-term Extension: Plans to randomize responders to monthly or quarterly maintenance dosing after week 52.
• Other Indications:
  • Vitiligo: Initiating a proof-of-concept study (~30 patients) in next few months; addressing unmet need in a market where only 15% of 1.9M US patients seek treatment.
  • Type 1 Diabetes: Ongoing TrialNet-sponsored Phase 2 study; data from first cohort expected late 2027.
  • Asthma: Exploring potential due to observed improvements in ACQ5 scores in AD patients with comorbid asthma.

Market and Competitive Outlook:

• Atopic Dermatitis Landscape:
  • Market Size: UK market expected to grow to >$30 billion by 2033; US market has >31 million patients with ~25% currently receiving systemic treatment.
  • Competitor Performance: IL-31 blocker (Namluvio) capturing ~10% of new starts 7 quarters post-launch; Dupixent's new-to-brand share dropped from 81% (2024) to 65% (current), with >50% of lost share going to novel MOAs.
  • Physician Sentiment: ~90% of surveyed dermatologists would consider starting a patient on RESPEG before existing biologics or JAK inhibitors.
  • Competitive Gap: No mid-to-late-stage agents addressing the heterogeneity of AD (Th1/Th2/Th17 pathways) like RESPEG's Treg mechanism; OX40 class setbacks viewed as clearing the path for novel mechanisms.
• Alopecia Areata Landscape:
  • Current standard of care (JAK inhibitors) requires daily dosing, carries boxed warnings, and involves lab monitoring; discontinuation often leads to loss of regrowth.
  • Vitiligo landscape dominated by JAK inhibitors (oral/topical) with safety concerns and lack of durable response post-treatment.

Macro / Industry Outlook:

• Regulatory Alignment: Positive feedback received from FDA, EMA, and PMDA regarding the combination with TCS for global registration.
• Disease Complexity: Emphasis on the highly heterogeneous nature of AD (biological drivers vary by patient) necessitating mechanisms beyond single-pathway blockade.
• Market Structure: Large addressable markets with low penetration (e.g., vitiligo 15%, AD systemic treatment 25%) support broad adoption of novel mechanisms.

Strategic Initiatives:

• Clinical Expansion:
  • Initiating Phase 3 Zenith AA study in December (earlier than previously planned).
  • Launching a new Investigator-Sponsored Trial (IST) for AA in moderate disease (vs. severe) starting H1 2027 (Mount Sinai).
  • Launching a Vitiligo PoC study (30 patients) in next few months (Mount Sinai).
• R&D Programs:
  • Continuing preclinical work on TNFR2 program (NECTAR-0166), a bispecific combining TNFR2 agonist with an undisclosed immune target.
  • Biomarker substudy (Mount Sinai) ongoing to correlate early IL-10/TGF-beta-1 elevations with clinical efficacy.
• Capacity/Capital: Strong balance sheet ($953M cash at Q3 end) supports the execution of the 2,400-patient Phase 3 Zenith program.

Risks and Headwinds to Outlook:

• Clinical/Regulatory: Failure to meet endpoints in Phase 3 studies (AD, AA, Vitiligo, T1D); potential delays in enrollment or data readouts.
• Competitive: Continued innovation by others in the space (STAT6, bispecifics) though management views the market as large enough to accommodate multiple winners.
• Operational: Execution of complex trial designs (off-treatment follow-ups, combination arms).
• General: Uncertainties inherent in biotechnology development, including mechanism of action validation and safety profiles.

Management Tone on the Future:

• Confidence Level: High. Management describes Q3 as "transformative," expresses "clear evidence" of market demand, and uses strong language regarding the "unique competitive position" and "differentiated mechanism."
• Hedges/Caveats: Standard forward-looking statement disclaimers regarding uncertainties and risks outside control.
• Strategic Pivot: Significant acceleration in AA study start (April to December) and early data release expectations (Vitiligo, T1D) indicates strong operational momentum and confidence in the pipeline.
• Differentiation: Strong belief that the Treg mechanism offers a "disease-modifying" potential (durability off-treatment) superior to current "symptom control" biologics and JAK inhibitors.

Miscellaneous:

• Enrollment Projections: All AD trials expected to complete enrollment around January 2029 to meet Summer 2028 data readouts.
• Safety Database: The combined 2,400-patient Zenith program aims to establish a substantial safety database.
• Investor Relations: Live webcast and replay available at Nectar.com; no updates to forward-looking statements except as required by law.